Favezelimab (anti-LAG-3) Plus Pembrolizumab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Cohort 3 of a Multicohort Open-Label Phase 1/2 StudyArmando Santoro,Nathalie A. Johnson,Kerry J. Savage,Abraham Avigdor,Ali Bazargan,Peter Borchmann,Robin Gasiorowski, Gareth P. Gregory,Yair Herishanu,Sumit Madan,Leonard Minuk,Gerardo Musuraca,Rachel Marceau West,Pallavi Pillai,Patricia Marinello,Pier Luigi ZinzaniBLOOD（2023）引用 0|浏览2暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
